Lupin receives Tentative Approval from U.S. FDA for Drospirenone Tablets

Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, to market a generic equivalent of Slynd® Tablets, 4 mg, of Exeltis USA Inc.

Drospirenone Tablets (RLD Slynd®) had estimated annual sales of USD 141 million in the U.S. (IQVIA MAT September 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 712.15 as compared to the previous close of Rs. 707.20. The total number of shares traded during the day was 13283 in over 702 trades.

The stock hit an intraday high of Rs. 713.60 and intraday low of 701.50. The net turnover during the day was Rs. 9428812.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA TentativeApproval ANDA DrospirenoneTablets